DoctorsGuide
Scientists have made a significant step forward in developing a test to help diagnose the early stages of Alzheimer's disease (AD) sooner and more accurately by measuring tau and beta-amyloid proteins in cerebrospinal fluid.
The study, published in the March 17 online issue of the Annals of Neurology, from the Alzheimer's Disease Neuroimaging Initiative (ADNI) not only confirmed that certain changes in biomarker levels in cerebrospinal fluid may signal the onset of mild AD, but also established a method and standard of testing for these biomarkers.
"Research indicates that Alzheimer's pathology causes....read the whole article
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Subscribe to:
Post Comments (Atom)
1 comment:
These types of discoveries are exactly why studies are so important. It is important for patients and families affected by diseases such as Alzheimer's to consider participating in clinical studies.
Another study to consider for Alzheimer’s is the ICARA (Bapi) study (www.icarastudy.com), whose goal is to explore if an investigational drug, called Bapineuzumab, can help slow the progression of Alzheimer's Disease.
Post a Comment